Background Increasing evidence has indicated that brain orexin plays a vital role in the regulation of gastrointestinal (GI) physiology such as gastric acid secretion and GI motility. The aim of this study was to elucidate the effects and mechanisms of orexin on gastric motility in non-fasted rats.
Introduction
Orexins/hypocretins are novel neuropeptides that are localized in neurons in the lateral hypothalamus [1, 2] . Orexins may be implicated in a wide variety of physiological functions. These include feeding [2, 3] , behavioral activity [4] , the sleep/awake cycle [5] , anxiety [6] , energy balance [7] , neuroendocrinological responses [8] , and cardiovascular functions [9] . In addition to these functions, we previously suggested, for the first, time that orexin-A was involved in the central regulation of gastric acid secretion [10] [11] [12] .
It has been shown that orexins bind to two specific receptors, named the orexin-1 (OX1R) and orexin-2 (OX2R) receptors. According to in vitro binding and functional assays, OX1R is selective for orexin-A and OX2R is non-selective for orexin-A and -B [2] . The effects of intracisternal (ic) injections of orexin-A and -B on gastric acid secretion were examined and it was clearly demonstrated that acid stimulation was induced by orexin-A but not by orexin-B [11] , suggesting that the orexin-A-induced stimulation of gastric functions may be mediated by OX1R.
Also, several researchers have recently reported that orexin-A mediates gastrointestinal (GI) motility. Bülbül et al. [13] demonstrated intracerebroventricular (icv) orexin-A-stimulated gastric contractions in non-fasted conscious rats. Kobashi et al. [14] showed that ic administration of orexin-A enhanced phasic contractions of the distal stomach, and this action was blocked by vagotomy in anesthetized rats. On the other hand, it has been reported that orexin-A accelerates gastric emptying through peripheral-and vagal-independent mechanisms [15] . Thus, the effects and mechanisms of orexin-A on GI motility have not been completely elucidated.
In this study, to investigate the role of brain orexin-A in the regulation of gastric motility, we investigated: (1) whether central or peripheral administration of orexin-A affects gastric motility and (2) whether endogenously released orexin-A in the brain plays a role in the regulation of gastric contractions in freely moving conscious rats.
Materials and methods

Animals
Male Sprague-Dawley rats weighing about 250 g were housed under controlled light/dark conditions (lights on 0700-1900 hours) with the room temperature regulated to 23-25°C. The rats were allowed free access to standard rat chow (solid rat chow; Oriental Yeast, Tokyo, Japan) and tap water.
Chemicals
Synthetic orexin-A (human/bovine/rat/mouse) was purchased from the Peptide Institute (Osaka, Japan) and dissolved in normal saline just before the experiments. A selective orexin-A antagonist, SB-334867 (Tocris Bioscience, Ellisville, MO, USA), was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO, USA). 2-Deoxy-D-glucose (2-DG), a central vagal stimulant, and atropine (Sigma-Aldrich) were dissolved in normal saline.
Implantation of catheter for manometric recordings
The rats were anesthetized with ether, and an open-tipped catheter (3-Fr, 1-mm internal diameter [ID]; Atom, Tokyo, Japan) for manometric measurement was placed at the gastric antrum, and fixed with purse-string sutures. The catheter was brought out through the abdominal wall musculature, tunneled subcutaneously to exit at the back of the neck, and secured to the skin. The rats were allowed to recover in individual cages for 2-5 days before the experiments.
Manometric recordings
Gastric motility was measured by manometric methods described in a previous study [16] . Conscious animals without fasting were put in wire-bottomed and nonrestraint polycarbonate cages. The manometric catheter from each animal was threaded through a flexible metal sheath (to protect it from biting) and connected to an infusion swivel (Instech Laboratories, Plymouth Meeting, PA, USA) to allow free movement. The catheter was connected to a pressure transducer (TP-400T; Nihon Kohden, Tokyo, Japan) and was continuously infused with degassed distilled water at a rate of 1.5 ml/h with a heavyduty pump (CVF-3100; Nihon Kohden). Pressure signals from the transducer were digitized and stored using a PowerLab system (AD Instruments, Colorado Springs, CO, USA). First, the basal state of the gastric pressure wave was measured for 1 h after 1 h of stabilization. Then the manometric catheter was disconnected and the rats were removed from the polycarbonate cages. Then orexin-A, SB-334867, 2-DG, atropine, or saline was injected intracisternally in a 10-ll volume, intravenously through the jugular vein in a 200-ll volume, and/or intraperitoneally in a 300-ll volume in rats under brief ether anesthesia. The ic injection was performed with a 10-ll Hamilton microsyringe after the rats had been mounted in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA) as reported previously [17] . After that, the rats were put in the cages again and the catheter was re-connected to a pressure transducer. The pressure wave was monitored for up to 2 h after injection. Using the recordings, we evaluated the motor index (MI) as described below.
Evaluation of MI
The MI was assessed by determining the area under the manometric trace (AUT). The AUT was calculated using data-acquisition software (LabChart v7; AD instruments). The baseline drifting and recording noise due to movement of the animals was very minor. To avoid any baseline drifting, we selected the analysis points with a stable baseline. The basal MI was determined by calculating the AUT for a 1-h period before drug administration. The %MI was calculated by the following formula: (AUT for each 1-h period after drug administration)/(basal MI) 9 100. In this experiment, pressure signals were continuously recorded for up to 4 h (1 h for stabilization, 1 h for basal MI, and 2 h for determining the changes induced by drugs), but the measurement was temporarily stopped in order to perform injections [ic, intraperitoneal (ip), or intravenous (iv)] in the middle of the recording process. In relation to the injections, we also needed time for the animals to recover from the anesthesia and time to re-stabilize the baseline manometric pressure in order to obtain adequate recordings for the analysis. Therefore, the manometric data obtained for approximately 5 min during the recovery and re-stabilization period were excluded from later analysis. Because atropine was administered 10 min before the ic orexin-A, the data for approximately 15 min during these preparations were excluded in that experiment.
Statistical analysis
Data were expressed as means ± SE. Comparison of %MI was performed using Student's t test. Statistica software (StatSoft, Tulsa, OK, USA) was used throughout the study.
Ethical considerations
The approval of the Research and Development and Animal Care committees at the Asahikawa Medical University (#11042, approved on March 7, 2011) was obtained for all studies.
Results
First, we examined the effect of orexin-A on gastric contractions in freely moving conscious rats. As demonstrated in Fig. 1 , ic injection of orexin-A (10 lg) stimulated gastric contractions, while saline administration did not affect the gastric motility. The stimulatory action of orexin-A was observed immediately after the ic injection and persisted for about 60 min. Therefore, we examined the MI change before and after orexin-A or saline injection for the first 1-h period. Figure 2 shows the MI change induced by the ic and ip injections of saline and orexin-A. The ic injection of saline did not change the MI (107.3 ± 4.78%), while orexin-A significantly increased the MI (169.6 ± 13.2%, p \ 0.05). On the other hand, ip injection of orexin-A did not have any effect on the MI (94.1 ± 6.4% for saline vs.
99.5 ± 8.1% for orexin-A, p [ 0.05), suggesting that orexin-A acts in the brain to stimulate gastric motility.
As demonstrated in Figs. 3 and 4, pretreatment with atropine (1 mg/kg, ip, 10 min before ic orexin-A) potently blocked the ic orexin-A-induced stimulation of gastric contractions and MI change (170.7 ± 10.3% for saline ? orexin-A vs. 117.3 ± 16.4% for atropine ? orexin-A, p \ 0.05), suggesting that the vagal cholinergic pathway plays a vital role in the stimulation of gastric motility by orexin-A. Figure 5 shows representative recordings of antral motility in rats treated with saline and 2-DG. As demonstrated, 2-DG (200 mg/kg) stimulated gastric motility immediately after iv injection and the stimulation lasted for more than 60 min. The MI was significantly increased in rats treated with 2-DG when compared with the saline control (183.0 ± 27.0% for 2-DG, n = 5, vs. 100.0 ± 5.9% for saline, n = 6, p \ 0.05).
Next, to test the hypothesis that endogenous orexin-A may be involved in the stimulation of gastric motility, we examined the effect of SB-334867, a selective OX1R antagonist, in the 2-DG stimulation of gastric motility model. The ic injection of this antagonist (40 lg) by itself did not change gastric contractions (Fig. 6) or the MI Fig. 1 Representative recordings of the gastric contractions in rats injected intracisternally with either orexin-A (10 lg) or saline. Asterisks indicate the period that was needed for intracisternal (ic) injection and re-stabilization of baseline manometric pressure. The manometric data obtained during this period were omitted from the analysis Fig. 2 The effect of orexin-A (10 lg) on gastric motility. Intracisternal (ic) injection of orexin-A significantly increased the motor index as compared to saline treatment. However, this effect was not observed with the intraperitoneal (ip) injection of orexin-A. Each column represents the mean ± SE. Numbers of rats are shown in parentheses. *p \ 0.05 versus saline-treated group (119.8 ± 9.6% for SB-334867, n = 7, vs. 107.1 ± 7.4% for DMSO, n = 5, p [ 0.05). On the other hand, ic SB-334867 (40 lg, immediately before iv 2-DG) potently blocked the 2-DG (200 mg/kg)-induced stimulation of gastric contractions (Fig. 7) and MI change (222.1 ± 28.8% for DMSO ? 2-DG vs. 122.9 ± 12.3% for SB-334867 ? 2-DG, p \ 0.05, Fig. 8 ).
Discussion
The gastric motility pattern in rats can be divided into the interdigestive and postprandial states. In fasted conscious rats, the injection of orexin-A into the cerebrospinal fluid changed the gastric motor pattern from interdigestive to postprandial [18] . On the other hand, in fed conscious rats, the administration of orexin-A into the cerebrospinal fluid stimulated gastric contractility [13] . Thus, orexin-A exogenously injected into the brain has an effect on gastric motility. However, the physiological relevance of brain orexin-A in the regulation of gastric motility remains to be clarified. We therefore investigated this issue in this study, using freely moving conscious rats.
First, we clarified that the central but not peripheral injection of orexin-A stimulated gastric motility. Bülbül et al. [13] have recently demonstrated that the icv administration of orexin-A increased gastric motility, this being in good agreement with the present data. However, whether peripherally injected orexin-A has any effect on gastric contractility has not been investigated. It was reported that continuous iv administration of orexin-A showed an inhibitory effect on the small intestinal migrating motility complex in the rat [19] . Moreover, Bülbül et al. [15] also demonstrated that endogenous orexin-A accelerated gastric emptying through peripheral mechanisms. These results suggest that orexin-A may also mediate GI motor function through a peripheral pathway. Orexin immunoreactivity is distributed in various regions of the alimentary tract [20] , and it was also demonstrated that orexin induced dosedependent contractions of intestinal segments in vitro [21] . Thus, orexin-A might act peripherally to have an effect on GI function. Because centrally injected orexin-A may leak into the periphery, we needed to exclude the possibility that when orexin-A was injected centrally it acted peripherally but not centrally to enhance gastric motility. The present data in freely moving conscious rats clearly demonstrated that the ip injection of orexin-A failed to stimulate gastric motility, strongly confirming that ic orexin-A acts centrally in the brain to stimulate gastric motility. We have very recently demonstrated that the ic injection of orexin-A significantly enhanced colonic motor function in conscious rats [22] , and the present study therefore provides evidence that orexin-A in the brain also stimulates gastric contractility in conscious rats.
Studies have demonstrated that the vagal system completely mediates 2-DG-stimulated gastric acid secretion [23, 24] . As demonstrated in the present study, pharmacological suppression of the vagal system by atropine potently blocked the ic orexin-A-induced stimulation of gastric motility, suggesting that orexin-A acts centrally in the brain to increase gastric motility through the vagal cholinergic pathway. Because the cells of origin innervating the stomach through the vagus nerve are located in the dorsal motor nucleus (DMN) of the vagus nerve [25] , the DMN neurons must be excited when orexin-A is injected into the cisterna magna. In fact, injection of orexin-A into the cerebrospinal fluid induced c-fos expression in a number of neurons including those of the DMN in rats [26] , further supporting the idea that the DMN neurons are excited when orexin-A is injected into the cerebrospinal fluid, as appeared to be the case in the present study. With regard to whether the DMN neurons are activated directly or indirectly by centrally administered orexin-A, two electrophysiological studies [27, 28] have demonstrated that orexin-A directly activates the DMN neurons in rat medullary slices. For instance, Grabauskas and Moises [27] have demonstrated, using whole-cell patch-clamp recordings in rat brainstem slices, that the application of orexin-A produced a slow depolarization dose-dependently, accompanied by increased firing of the DMN neurons that projected their axon terminals to the stomach. Although the excitatory responses persisted even after the application of tetrodotoxin, they were completely abolished by the application of Cd 2? , indicating that the effects of orexin are mediated by direct postsynaptic excitation of the DMN neurons via orexin receptors. In addition, immunocytochemical studies have shown that OX1R was highly expressed in neurons in the DMN [29] . These findings suggest that orexin-A directly excites the DMN neurons that project to the stomach. According to findings by Krowicki et al. [29] , microinjection of orexin-A into the DMN in anesthetized rats increased intragastric pressure and antral motility. Based upon these results, we could conclude that injection of orexin-A into the cerebrospinal fluid directly activates the DMN neurons, followed by an increase of the vagal tone, thereby stimulating gastric antral motility, as shown in the present study using freely moving conscious rats. 2-DG has been used as a tool for central activation of the vagal pathway. It is known that 2-DG stimulates the glucoprivic receptors in the lateral hypothalamic area (LHA), which in turn initiates and sustains the vagusmediated excitation of gastric function [30] . With regard to the effect of 2-DG on gastric motility, Quintana et al. [31] demonstrated iv 2-DG (200 mg/kg)-stimulated gastric contractions in urethane-anesthetized rats. So far, whether 2-DG is capable of stimulating gastric contractility in conscious rats also has not been reported. The present study clearly showed for the first time that the iv injection of 2-DG potently stimulated gastric motility in conscious rats.
Because some orexin-A-positive neurons in the LHA project to the DMN [32] , it appears that 2-DG activates orexin-A neurons in the LHA [33] , possibly to induce excitation of the DMN neurons, leading to the activation of vagal outflow to the stomach. It was suggested that both 2-DG and orexin-A stimulate gastric contractions through central activation of the vagal pathway [14, 31] . Based on these findings, we hypothesized that orexin-A in the brain might be involved in the 2-DG-induced stimulation of gastric contractions, and we used the model of 2-DGstimulated gastric motility in conscious rats to test this hypothesis.
SB-334867 is a non-peptide selective OX1R antagonist [34] , that has made it possible to examine the physiological role of orexin-OX1R pathways in biological actions. Bülbül et al. [13, 18] reported that the icv injection of SB-334867 (16 lg) enhanced gastric spontaneous phase-III like contractions in fasted rats and suppressed postprandial gastric contractions in non-fasted rats, suggesting that endogenous orexin-A changes the GI motor pattern from interdigestive to postprandial. However, in our study, the SB-334867 antagonist (40 lg) by itself did not change basal MI. This difference between our study and the findings of Bülbül et al. [13, 18] may be explained as follows. First, the routes of administration were different, i.e., icv and ic. Second, the doses of the antagonist were also different, the dose being 2.5 times higher in the present study. Also, the diffusion of chemicals into the cerebrospinal fluid in rats treated with icv or ic injections would be different, simply because of the different injection sites, i.e., 3rd ventricle (icv) versus 4th ventricle (ic), which may lead to differences in time-and dose-dependent chemical actions. In fact, Stengel et al. [35] have recently demonstrated that the icv, but not ic injection, of nesfatin-1 at the same dose inhibited gastric emptying in rats. They suggested that the chemical would reach the forebrain more easily by icv injection and that it would reach the hindbrain more easily by ic injection, leading to the different effects of nesfatin-1 on gastric emptying. Thus, the different routes might, at least in part, explain the different actions and doses of the orexin antagonist required to exert its activity. Our test dose (40 lg) administered by ic injection increased the frequency of phase-III like contractions of the colon in non-fasted rats, while 16 lg of this antagonist did not significantly change colonic motility (unpublished data). Accordingly, the dose of 40 lg administered by ic injection was thought to be adequate for examining the physiological role of endogenous orexin in GI motility in rats. As clearly shown in the present study, the ic injection of SB334867 (40 lg) significantly blocked the 2-DG-evoked stimulation of gastric motility. This result demonstrated for the first time that endogenous orexin-A in the brain mediates 2-DGstimulated gastric motility in conscious rats, possibly through acting via OX1R in the DMN neurons.
Based upon these lines of evidence, we constructed a schematic illustration of our hypothesis of the mechanism by which orexin-A acts in the brain to stimulate gastric motility (Fig. 9) . Orexin-A-containing neurons in the LHA project their terminals to the DMN and release orexin-A, which activates neurons in the DMN through acting via OX1R in these neurons, followed by activation of the vagal Fig. 9 Schematic illustration of our hypothesis of the mechanism by which orexin-A acts in the brain to stimulate gastric motility. Orexin-A-containing neurons in the lateral hypothalamic area (LHA) project their terminals to the dorsal motor nucleus (DMN) and release orexin-A, which activates neurons in the DMN in the medulla through acting via the orexin-1 receptor (OX1R) in the DMN neurons, followed by activation of the vagal efferent pathway, thereby stimulating gastric motility. Glucoprivation caused by 2-deoxy-D-glucose or cephalic phase stimulation might stimulate gastric motility through this signaling pathway J Gastroenterol (2012) 47:404-411 409 efferent pathway, thereby stimulating gastric motility. Glucoprivation caused by 2-DG might stimulate gastric motility through this signaling pathway. The cephalic phase of the GI response produces coordinated GI alterations that prime the gut to assist in the digestion of the impending meal. The alterations in response to cephalic stimulation in the stomach and pancreas, i.e., stimulation of gastric acid and pancreas exocrine secretion, are mimicked by orexin-A [11, 36] , suggesting this peptide to be a candidate molecule which triggers the process of cephalic phase stimulation [37] . The cephalic phase stimulation also mediates aspects of gastric motility, such as fundic accommodation and stimulation of antral contractions [38, 39] . The present study has revealed that endogenous orexin-A in the brain enhances antral contractions in conscious rats, further supporting our hypothesis that orexin-A in the brain mediates the response to cephalic phase stimulation. This speculation may be supported by a different point of view. 2-DG is known as a compound that inhibits glucose utilization (glucoprivation) and causes intracellular glucopenia [40] , followed by stimulation of the central vagal pathway. As shown in the present study, endogenously released orexin-A induced by central glucoprivation as a hunger state evoked the stimulation of gastric motility, supporting the hypothesis that orexin-A in the brain triggers cephalic phase stimulation (Fig. 9) .
Several neurotransmitters and neuromodulators that activate or inhibit orexin neurons have been identified [41] . One of these molecules, the peptide ghrelin, is reported to activate orexin neurons. With regard to the relation between orexin and ghrelin, Toshinai et al. [42] have demonstrated immunohistochemically the synaptic contact of ghrelin-containing axons with orexin-producing neurons in the rat hypothalamus. In addition, these authors also showed there was a functional interaction between ghrelin and orexin in the brain, according to the following findings. The icv administration of ghrelin stimulated food intake, and this action of ghrelin was attenuated by pretreatment with an anti-orexin-A antibody. It was further shown that the ghrelin-induced feeding was suppressed in orexin knockout mice. These data suggest that ghrelin increases food intake through the action of the orexin system in the brain. Because ghrelin is involved in the regulation of GI functions [43] , this suggests that further studies should be performed to clarify the relationship between these two peptides in the brain in the control of gastric motility.
Functional gastrointestinal disorders (FGIDs) are characterized as chronic or recurrent GI symptoms that are not explained by structural or biochemical abnormalities. Brain-gut interaction plays an important role in the pathophysiology of FGIDs [44] . Based upon the reported actions of central orexin-A on body functions such as GI function, appetite, the sleep/awake cycle, and mood state, we hypothesized that decreased orexin signaling may be involved in the pathophysiology of FGID [45] . Patients with functional dyspepsia (FD), which is one of the FGIDs, frequently complain of GI symptoms after meals, and postprandial antral hypomotility and reduced fundic accommodation were reported to be some of the physiological mechanisms of FD [46, 47] . As shown in the present study, fundic accommodation [14] and hypermotility in the distal stomach were observed in rats treated with central orexin-A, indicating that decreased orexin signaling may contribute to the pathophysiology of FD. In this context, exploring the physiological role of orexin in GI motility may pave the way for further understanding of the pathophysiology and improvement of the therapy of FD.
